Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

Don't Call It a Comeback

View original at nasdaq.com
Don't Call It a Comeback In this podcast, Motley Fool contributors Travis Hoium, Jon Quast, and Rachel Warren discuss: Chipotle's drop and falling same-store sales.Target's lost identity.Crocs' value…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Target has 53 years of consecutive dividend increases

    80% confidence
  • Over the long-term, stock price is correlated with profits

    80% confidence
  • Crocs share count is down about 16% over the last three years

    80% confidence
  • Chipotle is in a very strong financial position with 1.5 billion in net income over the past year, 1.8 billion in cash and investments, and no debt other than lease liabilities

    80% confidence
  • Chipotle plans to open 350-370 new restaurants in 2026

    80% confidence
  • Would be very hesitant to say Chipotle's best days are over

    80% confidence
  • Target has an A credit rating and just under 5 billion in cash

    80% confidence
  • Target's digital businesses (third party marketplace and digital advertising) have potential to help financials, but require stabilization of core retail operations

    80% confidence
  • Chipotle's board authorized an additional $1.8 billion in share repurchases

    80% confidence
  • Crocs is the number one footwear brand on TikTok shop in the US

    80% confidence
  • Chipotle opened about 200 new locations over the last three quarters, with average unit volumes dropping about 3%

    80% confidence
  • Target stock price has already hit its low point and can make a comeback

    80% confidence
  • Target is doubling down on what's not working with remodels and private label strategy

    80% confidence
  • Crocs has a comeback in store and will be a market beater over the next five years

    80% confidence
  • About 40% of Chipotle sales come from households earning under $100,000 annually

    80% confidence
  • Target plans to drive over $15 billion in revenue growth over the next five years

    80% confidence
  • Growth is a component of value

    80% confidence
  • Crocs management overestimated growth potential for Hey Dude and stuffed wholesale channels full of merchandise

    80% confidence
  • Chipotle is dealing with cyclical headwinds, not structural issues

    80% confidence
  • Chipotle has almost 4,000 locations and thinks it can add 3,000 more

    80% confidence
  • Crocs has the clearest path toward a comeback because it has the clearest explanation of what has gone wrong

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com